| 000 | 01669 a2200457 4500 | ||
|---|---|---|---|
| 005 | 20250517090353.0 | ||
| 264 | 0 | _c20180112 | |
| 008 | 201801s 0 0 eng d | ||
| 022 | _a1520-6777 | ||
| 024 | 7 |
_a10.1002/nau.23009 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aPeyronnet, Benoit | |
| 245 | 0 | 0 |
_aIntradetrusor injections of onabotulinum toxin A (Botox®) 300 U or 200 U versus abobotulinum toxin A (Dysport®) 750 U in the management of neurogenic detrusor overactivity: A case control study. _h[electronic resource] |
| 260 |
_bNeurourology and urodynamics _c03 2017 |
||
| 300 |
_a734-739 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAdministration, Intravesical |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aBotulinum Toxins, Type A _xadministration & dosage |
| 650 | 0 | 4 | _aCase-Control Studies |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aNeuromuscular Agents _xadministration & dosage |
| 650 | 0 | 4 | _aRetrospective Studies |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 |
_aUrinary Bladder, Neurogenic _xdrug therapy |
| 650 | 0 | 4 |
_aUrinary Bladder, Overactive _xdrug therapy |
| 650 | 0 | 4 |
_aUrodynamics _xdrug effects |
| 700 | 1 | _aCastel-Lacanal, Evelyne | |
| 700 | 1 | _aRoumiguie, Mathieu | |
| 700 | 1 | _aEven, Lucie | |
| 700 | 1 | _aMarque, Philippe | |
| 700 | 1 | _aSoulié, Michel | |
| 700 | 1 | _aRischmann, Pascal | |
| 700 | 1 | _aGame, Xavier | |
| 773 | 0 |
_tNeurourology and urodynamics _gvol. 36 _gno. 3 _gp. 734-739 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1002/nau.23009 _zAvailable from publisher's website |
| 999 |
_c25886325 _d25886325 |
||